Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Valerio Therapeutics - Asset Resilience Ratio
Valerio Therapeutics (ALVIO) has an Asset Resilience Ratio of 12.90% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Valerio Therapeutics's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Valerio Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €2.64 Million | 12.9% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €2.64 Million | 12.90% |
Asset Resilience Insights
- Moderate Liquidity: Valerio Therapeutics has 12.90% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Valerio Therapeutics Industry Peers by Asset Resilience Ratio
Compare Valerio Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Valerio Therapeutics (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Valerio Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.57% | €1.18 Million | €17.93 Million | -12.76pp |
| 2023-12-31 | 19.33% | €6.82 Million | €35.27 Million | -14.52pp |
| 2022-12-31 | 33.85% | €14.59 Million | €43.09 Million | +0.14pp |
| 2021-12-31 | 33.71% | €17.89 Million | €53.06 Million | +2.48pp |
| 2020-12-31 | 31.23% | €14.52 Million | €46.51 Million | +31.51pp |
| 2018-12-31 | -0.28% | €-177.00K | €63.25 Million | -0.22pp |
| 2017-12-31 | -0.06% | €-50.00K | €78.07 Million | -4.30pp |
| 2016-12-31 | 4.24% | €5.30 Million | €125.10 Million | +0.13pp |
| 2015-12-31 | 4.11% | €5.31 Million | €129.24 Million | -37.36pp |
| 2013-12-31 | 41.46% | €7.36 Million | €17.74 Million | -34.24pp |
| 2011-12-31 | 75.70% | €25.80 Million | €34.08 Million | -0.89pp |
| 2010-12-31 | 76.59% | €20.17 Million | €26.33 Million | +11.45pp |
| 2009-12-31 | 65.14% | €13.90 Million | €21.34 Million | -8.50pp |
| 2008-12-31 | 73.64% | €31.20 Million | €42.37 Million | -14.83pp |
| 2007-12-31 | 88.47% | €56.21 Million | €63.54 Million | +11.24pp |
| 2006-12-31 | 77.23% | €17.54 Million | €22.71 Million | -9.87pp |
| 2005-12-31 | 87.09% | €28.95 Million | €33.24 Million | -- |